4 news items
Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
TAK
19 Mar 24
Anderson Cancer Center and lead investigator of the PhALLCON trial. "Ponatinib may help address these factors and impact long-term outcomes."ICLUSIG
Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year
TAK
13 Feb 24
priority, but one or multiple non-RCT designs will be considered, and to involve CIRC members. Investigators who have pilot data and partner support
- Prev
- 1
- Next